MediWound Ltd. Q4 2025 Earnings Call Summary

Moby Intelligence

Thu, March 5, 2026 astatine 11:35 AM CST 3 min read

• The institution successfully commissioned an expanded manufacturing facility, expanding NexoBrid accumulation capableness sixfold to conscionable anticipated planetary demand.

• Revenue for 2025 was impacted by the U.S. authorities shutdown, which delayed fund approvals and the initiation of caller improvement work contracts.

• The Phase III VALUE proceedings for EscharEx successful venous limb ulcers (VLU) is advancing arsenic planned, with the bulk of objective sites present progressive and enrolling.

• Strategic enlargement of the EscharEx programme into diabetic ft ulcers (DFU) and unit ulcers aims to seizure the 3 large chronic coiled indications.

• Gross borderline betterment successful 2025 was driven by a much favorable gross premix contempt little wide top-line results.

• Management maintains operational resilience and subject successful Israel contempt ongoing determination conflict, ensuring objective and commercialized milestones stay connected track.

• Industry validation continues to turn done probe collaborations with 7 market-leading coiled attraction companies, including a caller concern with B. Braun.

• Revenue guidance of $24 cardinal to $26 cardinal for 2026 assumes regulatory support of the expanded manufacturing installation and resumed BARDA/DOW support.

• The 2028 gross people of $50 cardinal to $55 cardinal includes the archetypal imaginable commercialized contributions from EscharEx, taxable to regulatory approval.

• Management expects to implicit the EscharEx Phase III VALUE proceedings enrollment and behaviour a prespecified interim appraisal by year-end 2026.

• Future maturation strategy prioritizes nationalist preparedness initiatives, including stockpiling and collaboration with subject and exigency effect systems.

• The institution plans to initiate a Phase II survey successful diabetic ft ulcers and an investigator-initiated survey successful unit ulcers during 2026.

• The U.S. authorities shutdown served arsenic a superior headwind successful 2025, causing a $7.0 cardinal gross shortfall compared to archetypal expectations.

• A $30.0 cardinal registered nonstop offering and warrant exercises strengthened the equilibrium expanse to $53.6 cardinal successful currency astatine year-end.

• R&D expenses accrued importantly to $14.0 cardinal successful 2025, reflecting the intensified concern required for the EscharEx Phase III program.

• Commercial merchandise of merchandise from the caller manufacturing tract is contingent upon regulatory approvals expected successful 2026.

• Capacity has accrued sixfold, but commercialized output from the caller tract is taxable to regulatory approvals expected successful precocious 2026.

• Management noted that existent request crossed territories exceeds existent manufacturing capabilities, though they person guided conservatively based connected expected clearance timelines.